TEVA.TA - Teva Pharmaceutical Industries Limited

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
7,000.00
-261.00 (-3.59%)
At close: 5:24PM IST
Stock chart is not supported by your current browser
Previous Close7,261.00
Open7,378.00
Bid6,999.00 x 200
Ask7,000.00 x 34100
Day's Range6,900.00 - 7,380.00
52 Week Range38.20 - 7,380.00
Volume4,049,751
Avg. Volume1,574,268
Market Cap71.12B
Beta-0.58
PE Ratio (TTM)N/A
EPS (TTM)-5.87
Earnings DateFeb 8, 2018
Forward Dividend & Yield1.36 (7.11%)
Ex-Dividend Date2017-03-02
1y Target Est23.33
  • How Hospitals Plan To Put Pressure On Generic-Drug Makers
    Investor's Business Daily7 hours ago

    How Hospitals Plan To Put Pressure On Generic-Drug Makers

    Generic-drug makers were hit Thursday after hospitals said they would make medicines themselves to circumvent high prices.

  • American City Business Journals8 hours ago

    Teva cutting 200+ local jobs as part of broader restructuring plan

    Teva Pharmaceutical Industries will be laying off more than 200 local employees as part of a major restructuring plan designed to save the company $3 billion by the end of 2019. The Israeli generic drug maker, which calls North Wales, Pa. its U.S. headquarters, said last month it would eliminate 14,000 positions globally — more that 25 percent of its total work force — over the next two years. It has about 56,000 employees worldwide including about 2,000 people in North Wales, West Chester and Frazer, Pa.

  • Teva's Trisenox Gets FDA Approval as First-Line Treatment
    Zacks3 days ago

    Teva's Trisenox Gets FDA Approval as First-Line Treatment

    Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.

  • Business Wire4 days ago

    Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia

    Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has approved the use of TRISENOX® injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia whose APL is characterized by the presence of the t translocation or PML/RAR-alpha gene expression.

  • Teva's Debt Cut to Junk by Moody's, Adding to Drugmaker's Woes
    Bloomberg6 days ago

    Teva's Debt Cut to Junk by Moody's, Adding to Drugmaker's Woes

    Teva Pharmaceutical Industries Ltd.’s credit rating was cut into junk territory by Moody’s Investors Service, adding to the company’s woes as revenue from its bestselling drug drops and it sells assets ...

  • MarketWatch6 days ago

    Teva credit rating downgraded to junk status at Moody's

    Teva Pharmaceuticals Industries Ltd.'s credit rating was downgraded two notches into junk status at Moody's Investors Service, which cited concerns over the drug maker's sizable debt. The rating agency ...

  • Moody's6 days ago

    Teva Pharmaceutical Finance Netherlands II BV -- Moody's downgrades Teva to Ba2; outlook stable

    Rating Action: Moody's downgrades Teva to Ba2; outlook stable. Global Credit Research- 12 Jan 2018. New York, January 12, 2018-- Moody's Investors Service downgraded the senior unsecured ratings of Teva ...

  • The Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017
    Motley Fool8 days ago

    The Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017

    Teva threw everything but the kitchen sink at its shareholders last year, but the future is beginning to look brighter.

  • MarketWatch8 days ago

    Mylan sees opportunity in rival Teva’s weakness

    Challenging conditions in the U.S. generic drug market have hit drugmaker Teva Pharmaceutical Industries Ltd. particularly hard.

  • Forbes8 days ago

    Teva's Stock Price Surge Against Its Predictable Woes

    Behind Teva's decline is the psychological tendency to take imprudent risks instead of accepting outcomes viewed as losses. There is a strong case to be made that this tendency drove Teva's board and executives to overpay for acquisitions and to delay cost cutting. This was predictable.

  • Reuters8 days ago

    Teva Pharm agrees with workers on closing Jerusalem inhaler plant

    Israel's Teva Pharmaceutical Industries said on Wednesday it had reached an agreement with workers on closing its inhaler factory in Jerusalem by the end of 2019, ending weeks of labour unrest at the facility. Since the cost-cutting plan was announced last month, workers from the inhaler plant have been disrupting operations. Under the agreement reached between Teva, the Histadrut labour federation and company unions, up to 60 workers will leave the company by the end of February, while the remaining 180 will remain until the facility is shut in December 2019.

  • Reuters9 days ago

    Teva Pharm directors cut their salaries in half: board member

    The board of directors at Teva Pharmaceutical Industries (TEVA.TA) (TEVA.N), which is reducing its workforce by more than a quarter as part of a global overhaul, has taken a 50 percent pay cut, a board member said on Wednesday. "This pay cut that the board took upon itself was done the same day that the cuts and job reductions were discussed," board member Dan Suesskind said at the Israel Business Conference in Jerusalem.

  • Reuters9 days ago

    Teva Pharm directors cut their salaries in half - board member

    The board of directors at Teva Pharmaceutical Industries (TEVA.TA) (TEVA.N), which is reducing its workforce by more than a quarter as part of a global overhaul, has taken a 50 percent pay cut, a board member said on Wednesday. "This pay cut that the board took upon itself was done the same day that the cuts and job reductions were discussed," board member Dan Suesskind said at the Israel Business Conference in Jerusalem.

  • Reuters9 days ago

    Teva Pharm agrees with workers on closing Jerusalem inhaler plant

    Israel's Teva Pharmaceutical Industries said on Wednesday it had reached an agreement with workers on closing its inhaler factory in Jerusalem by the end of 2019, ending weeks of labour unrest at the facility. Since the cost-cutting plan was announced last month, workers from the inhaler plant have been disrupting operations. Under the agreement reached between Teva, the Histadrut labour federation and company unions, up to 60 workers will leave the company by the end of February, while the remaining 180 will remain until the facility is shut in December 2019.

  • Benzinga10 days ago

    Teva's Cost-Cutting Plan Nets A Mizuho Upgrade

    After a turbulent 2017 , Mizuho analysts now see upside potential for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA )'s stock. The Analyst Mizuho Securities USA's Irina Koffler upgraded Teva's stock ...

  • Barrons.com10 days ago

    Teva Tightens Belt, Now a Buy

    Shares of Teva  Pharmaceuticals (TEVA) are higher on Tuesday, on the heels of an upgrade from Mizuho. Koffler writes that Teva's cost cut targets are both "conservative and achievable." That said, she did lower her 2018 sales estimates just below consensus expectations, to account for a "major clean-up" of the generics business and what she anticipates will be conservative guidance for the year. Share of Teva are up 0.9% to $19.28 this morning.

  • The Big Reason Teva Pharmaceutical Industries Catapulted 28% Higher in December
    Motley Fool10 days ago

    The Big Reason Teva Pharmaceutical Industries Catapulted 28% Higher in December

    Plans to "trim the fat" have Wall Street and investors excited.

  • 24/7 Wall St.11 days ago

    Why Alder Biopharma Is Winning Big on Monday

    Alder Biopharmaceuticals saw its shares make a solid gain on Monday amid a blizzard of updates from the company.

  • Teva Pharmaceutical Industries Ltd’s (ADR) (TEVA) GmbH and Alder BioPharmaceuticals Form Global License Agreement
    SmarterAnalyst11 days ago

    Teva Pharmaceutical Industries Ltd’s (ADR) (TEVA) GmbH and Alder BioPharmaceuticals Form Global License Agreement

    Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced that its subsidiary, Teva Pharmaceuticals International GmbH., has signed a global license agreement with Alder BioPharmaceuticals. The agreement validates Teva’s IP and resolves Alder’s opposition to Teva’s European Patent No. 1957106 B1, with respect to anti-calcitonin gene-related peptide (CGRP) antibodies and methods for their use. It also provides Alder with clarity for its ongoing plans in the field.

  • Business Wire11 days ago

    Teva Announces Global License Agreement with Alder BioPharmaceuticals® in the Field of Anti-CGRP-Based Therapy

    Teva Pharmaceutical Industries Ltd.,  today announced that its subsidiary, Teva Pharmaceuticals International GmbH., has signed a global license agreement with Alder BioPharmaceuticals.

  • 2 Reasons Why Allergan Stock Plunged in 2017
    Motley Fool11 days ago

    2 Reasons Why Allergan Stock Plunged in 2017

    Allergan's shares fell off a cliff last year. Can it rebound in 2018?

  • Benzinga13 days ago

    Teva Vs Mylan: Wells Fargo Weighs In

    The past year has been a rollercoaster ride for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA ) and its investors. But even with the stock down 48.6 percent in the past year, investors may have ...

  • Reuters14 days ago

    Teva admin staff in Israel agree to improved redundancy packages

    Teva Pharmaceutical Industries reached agreement with Israel's Histadrut labour federation on Thursday to award preferential severance packages to company administrative staff taking voluntary redundancy, both sides said in a statement. Under a two-year plan, Teva aims to reduce costs by $3 billion by the end of 2019, from about $16.1 billion in 2017. Some 1,700 jobs are expected to be lost in Israel and workers have protested since the cuts were announced.

  • Business Wire15 days ago

    Teva to Present at the 36th Annual J.P. Morgan Healthcare Conference

    Teva Pharmaceutical Industries Ltd. will host a live audio webcast at the 36th Annual J.P. Morgan Healthcare Conference. Kåre Schultz, President & CEO will present on Monday, January 8, 2018 at 9:30 AM PST.

  • Reuters16 days ago

    Drugmakers raise 2018 U.S. prices, stick to self-imposed limits

    Drugmakers opened the new year by raising U.S. prices on dozens of medicines, but early data showed the increases generally remained within a 10 percent self-imposed limit in response to a backlash from consumers and politicians. Soaring U.S. prices for both branded and generic drugs have sparked public outrage and government investigations over the past few years. "Drug price increases are somewhat more constrained in 2017 and 2018 than they have been previously," Cowen and Co analyst Eric Schmidt said.